[PDF] Top 20 ABO incompatibility in mismatched unrelated donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia: A report from the acute leukemia working party of the EBMT.
Has 10000 "ABO incompatibility in mismatched unrelated donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia: A report from the acute leukemia working party of the EBMT." found on our website. Below are the top 20 most common "ABO incompatibility in mismatched unrelated donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia: A report from the acute leukemia working party of the EBMT.".
ABO incompatibility in mismatched unrelated donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia: A report from the acute leukemia working party of the EBMT.
... demographics A total of 1,013 AML patients who underwent HLA mismatched allo- geneic stem cell transplantation between 2005 and 2014 was identi- fied and ...most of the ... Voir le document complet
8
The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50 years—a report from the EBMT acute leukemia working party
... endpoints of the study were incidences and se- verity of acute and chronic GVHD, NRM, and disease relapse incidence ...was the date of trans- plant for all ...NRM ... Voir le document complet
15
Umbilical cord blood versus unrelated donor transplantation in adults with primary refractory or relapsed acute myeloid leukemia: a report from Eurocord, the Acute Leukemia Working Party and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the EBMT
... is a retrospective, multicenter registry-based study performed by the Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow ... Voir le document complet
8
Umbilical cord blood versus unrelated donor transplantation in adults with primary refractory or relapsed acute myeloid leukemia: a report from Eurocord, the Acute Leukemia Working Party and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the EBMT.
... is a retrospective, multicenter registry-based study performed by the Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow ... Voir le document complet
7
Unrelated cord blood transplantation for adult patients with acute myeloid leukemia: Higher incidence of acute graft-versus-host disease and lower survival in male patients transplanted with female unrelated cord blood-a report from Eurocord, the Acute Leukemia Working Party, and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the European Group for Blood and Marrow Transplantation
... is a retrospective study performed by the Acute Leukemia Working Party (ALWP) of the European Group for Blood and Marrow Transplantation (EBMT) ... Voir le document complet
11
Prediction of Allogeneic Hematopoietic Stem-Cell Transplantation Mortality 100 Days After Transplantation Using a Machine Learning Algorithm: A European Group for Blood and Marrow Transplantation Acute Leukemia Working Party Retrospective Data Mining Study
... model for overall mortality (OM) at day 100. The ADT consists of alternating levels of prediction (ellipses) and decision nodes ...with a weight, representing its contribution to ... Voir le document complet
10
Unrelated cord blood transplantation for adult patients with acute myeloid leukemia: higher incidence of acute graft-versus-host disease and lower survival in male patients transplanted with female unrelated cord blood—a report from Eurocord, the Acute Leukemia Working Party, and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the European Group for Blood and Marrow Transplantation
... is a retrospective study performed by the Acute Leukemia Working Party (ALWP) of the European Group for Blood and Marrow Transplantation (EBMT) ... Voir le document complet
12
Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
... on the AML risk pro file and stage and the pre- sence or absence of minimal residual disease (MRD) [ 1 – 3 ...accounts for ~ 40% of treatment failures, with a preponderance ... Voir le document complet
12
Matched and mismatched unrelated donor compared to autologous stem cell transplantation for acute myeloid leukemia in first complete remission: a retrospective, propensity score-weighted analysis from the ALWP of the EBMT
... Keywords: Acute myeloid leukemia (AML), Allogeneic transplantation, Matched (10/10) and mismatched (9/10) unrelated donor transplantation, Autologous ... Voir le document complet
15
Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT
... Haplo-identical hematopoietic stem cell transplantation (haplo-SCT) is an attractive transplant procedure since it provides a possibility of transplantation to almost all ... Voir le document complet
13
Allogeneic hematopoietic cell transplantation with cord blood versus mismatched unrelated donor with post-transplant cyclophosphamide in acute myeloid leukemia
... was a retrospective multicenter analysis using the dataset of the Acute Leukemia Working Party (ALWP) of the European Society for Blood and ... Voir le document complet
12
Reduced-Intensity Conditioning With Fludarabine and Busulfan Versus Fludarabine and Melphalan for Patients With Acute Myeloid Leukemia: A Report From the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation
... Group for Blood and Marrow Transplantation (EBMT). The EBMT registry is a voluntary working group of more than 500 transplant centers; its participants are required ... Voir le document complet
8
Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors
... is a retrospective study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation ... Voir le document complet
11
Management of patients with acute leukemia during the COVID-19 outbreak: practical guidelines from the acute leukemia working party of the European Society for Blood and Marrow Transplantation
... Severe acute respiratory syndrome coronavirus-2 (SARS- CoV-2) is the novel coronavirus first detected in Wuhan, ...options in Europe and there is no available vaccine. Reports from ... Voir le document complet
5
Stability of the cell dynamics in acute myeloid leukemia
... stability of the nonlinear time-delay model Our next objective is to show that inequalities (25) are sufficient for the global asymptotic stability of the zero solution of ... Voir le document complet
22
Allogeneic hematopoietic stem cell transplantation for T-prolymphocytic leukemia: a report from the French society for stem cell transplantation (SFGM-TC)
... follow-up, the relapse incidence was 47% (Fig. 1B). Relapse was observed at a median of ...Among the 11 patients who relapsed, the relapse was observed beyond 1 yr for five ... Voir le document complet
5
Prediction of Hematopoietic Stem Cell Transplantation Related Mortality-Lessons Learned from the In-Silico Approach: A European Society for Blood and Marrow Transplantation Acute Leukemia Working Party Data Mining Study
... encountered. A new score, based on integrated feature of the comorbidity index and EBMT score, was constructed achieving an AUC of ...AUC of 0.65 using only 3–5 variables. Adding ... Voir le document complet
15
Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Intermediate or High-Risk Acute Myeloid Leukemia in Complete Remission: a Study From the ALWP of the EBMT
... time from diagnosis to transplant CR1 patients, days (range) CR2 patients, days (range) 627 (135-1701) 135 (43-225) 631 (135-1508) 130 (43-948) 547 (166-1701) 154 (43-827) ... Voir le document complet
22
Use of Tyrosine Kinase Inhibitors to Prevent Relapse After Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Position Statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
... The introduction of the BCR-ABL–directed tyrosine kinase inhibitors (TKIs) to the front-line therapy for Ph- positive ALL has improved CR rates, the quality of responses, ... Voir le document complet
11
Comparison of mycophenolate mofetil and calcineurin inhibitor versus calcineurin inhibitor-based graft-versus-host-disease prophylaxis for matched unrelated donor transplant in acute myeloid leukemia. A study from the ALWP of the EBMT
... GRFS acute GvHD II-IV acute GvHD III-IV chronic GVHD extensive chronic GvHD CSA alone 26% [20-33] 21% [16-28] 52% [45-60] 55% [47-63] 40% [32-47] 27% [21-33] 9% [6-14] 38% [31-45] 17% [11-23] CSA+MMF 24% ... Voir le document complet
26
Sujets connexes